Auspex Pharmaceuticals Garners $25,000,000 Series D Funding Round

  • Feed Type
  • Date
    11/9/2012
  • Company Name
    Auspex Pharmaceuticals
  • Mailing Address
    3366 North Torrey Pines Court La Jolla, CA 92037
  • Company Description
    Auspex Pharmaceuticals is a developer of next-generation medicines with improved safety and performance and a pioneer in the targeted application of deuterium chemistry to clinically validated drugs. For more than five years the company has worked to apply its targeted deuteration strategy to drug molecules across multiple therapeutic areas, secure a proprietary position on several hundred compounds and initiate development on multiple clinical candidates.
  • Website
    http://www.auspexpharma.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $25,000,000
  • Transaction Round
    Series D
  • Proceeds Purposes
    Auspex will use the funds to advance the development of its portfolio of drug molecules, particularly the Phase 3 development of its lead molecule, SD-809, expected to begin in the first half of 2013.
  • M&A Terms
  • Venture Investor
    Panorama Capital
  • Venture Investor
    Thomas, McNerny & Partners
  • Venture Investor
    CMEA Capital